Doc code :IDS

PTO/SB/08a (09-08)

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 10/31/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10609147		
	Filing Date		2003-06-27		
INFORMATION DISCLOSURE	First Named Inventor	Ronal	ld Knegtel		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1624		
(Not for submission under 57 of K 1.33)	Examiner Name	Paul \	/. Ward		
	Attorney Docket Numb	er	VPI/02-110 US		

					U.S.	PATENTS		-		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	) Date	Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relev- Figures Appear	
	1									
If you wish	n to ac	ı dd additional U.S. Pateı	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ation	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		e /ant
÷	1	20040242494	A1	2004-12	2-02	Vertex Pharmaceuticals, Inc.				
If you wish	n to ac	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Add	d butto	on.	
				FOREIG	GN PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> į		Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	WO 95/35308	wo		A1	1995-12-28	Vertex Pharmaceuticals, Inc.			
	2	EP 07/61680	EP .		A2	1997-12-03	Vertex Pharmaceut Inc.	icals,		
	3	WO 97/22619	wo		A2	1997-06-26	Vertex Pharmaceuti Inc.	icals,		

·					Application Number				10609147			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)			Filing Date				2003-06-27					
			First N	First Named Inventor Rona			ald Knegtel					
			Art Unit				1624					
			Examiner Name Paul			Paul	I V. Ward					
				Attorney Docket Number			er	VPI/02-110 US				
	4	wo o	06/057961	wo		A1	2006-06-0	11	Vertex Pharmaceuticals, Inc.			
If you wis	h to a	dd add	litional Foreign F	Patent Do	cument	citation	information	on ple	ease click the Add buttor	1		
			<del>-</del>	NON	-PATE	NT LITE	ERATURE	DOC	UMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								<b>T</b> 5		
	1	GOLEC, et al., "Structure-Based Design of Non-Peptidic Pyridone Aldehydes as Inhibitors of Interleukin-1β Converting Enzyme", Bioorganic & Medicinal Chemistry Letters (1997), vol. 7, no. 17, pp. 2181 - 2186.										
	2	SEMPLE, et al., "Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-1β-Converting Enzyme (ICE)", Bioorganic & Medicinal Chemistry Letters (1998), vol. 8, pp. 959-964.										
If you wis	h to a	dd add	ditional non-pate	nt literatu	re docu	ment ci	tation infor	matic	on please click the Add I	outton		
							R SIGNA	TURE				
Examiner Signature /Paul Ward/ (01					/25/20	09)			Date Considered			

<sup>1</sup> See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.